Biopticon

Executive Summary

Biopticon is a private, preclinical-stage company headquartered in Cambridge, MA, specializing in advanced tumor measurement and management solutions for oncology research. Founded in 2003, the company has developed the Tumor Management System, comprising the TumorImager-2—a 3D scanning device that provides high-precision volumetric measurements of tumors—and the TumorManager software platform for streamlined xenograft study management. By combining diagnostic hardware with AI-driven analytics, Biopticon addresses a critical pain point in preclinical oncology: the need for accurate, reproducible, and non-invasive tumor quantification to accelerate drug development. With over two decades of domain expertise, Biopticon is positioned as a niche leader in the preclinical imaging market, catering to pharmaceutical companies and contract research organizations (CROs) conducting in vivo efficacy studies. The company's focus on AI/ML integration enables automated data analysis and longitudinal tracking, reducing manual errors and improving throughput. Despite being in the preclinical stage, Biopticon's established product portfolio and targeted customer base suggest potential for commercial growth as the demand for high-fidelity imaging tools rises with the expansion of oncology pipelines. Key risks include limited financial transparency—total raised and valuation are undisclosed—and reliance on a narrow product line. However, the company's unique value proposition and entry barriers in specialized imaging afford it a defensible market position.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for TumorImager-240% success
• Q4 2026Strategic partnership with a top-10 pharma company30% success
• Q3 2026Launch of TumorManager v2.0 with AI-powered analytics50% success